GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » 3-Year Book Growth Rate

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) 3-Year Book Growth Rate : -9.90% (As of Dec. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Teva Pharmaceutical Industries 3-Year Book Growth Rate?

Teva Pharmaceutical Industries's Book Value per Share for the quarter that ended in Dec. 2023 was $6.70.

During the past 12 months, Teva Pharmaceutical Industries's average Book Value per Share Growth Rate was -4.70% per year. During the past 3 years, the average Book Value per Share Growth Rate was -9.90% per year. During the past 5 years, the average Book Value per Share Growth Rate was -14.00% per year. During the past 10 years, the average Book Value per Share Growth Rate was -15.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Teva Pharmaceutical Industries was 47.20% per year. The lowest was -24.10% per year. And the median was 16.70% per year.

Competitive Comparison of Teva Pharmaceutical Industries's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's 3-Year Book Growth Rate falls into.


Teva Pharmaceutical Industries 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Teva Pharmaceutical Industries  (NYSE:TEVA) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Teva Pharmaceutical Industries 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » 3-Year Book Growth Rate
Comparable Companies
XTAE:KMDA XTAE:REKA XTAE:TKUN XTAE:PNAX XTAE:NXTG XTAE:CNTC XTAE:PMCN-M ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN TSE:4507 VTRS NBIX XSWX:SDZ SZSE:000538 BOM:500124 BOM:532321 TSE:4523
Traded in Other Exchanges
TEVJF:USA TEVA:Mexico TEVA:Israel 0LER:UK TEV:Germany TEV:Germany TEV:Germany T1EV34:Brazil TEVA:Austria
Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Website
https://www.tevapharm.com
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Executives
Dov Bergwerk officer: Acting Chief Legal Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif officer: EVP, Chief Financial Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss officer: Chief Accounting Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant officer: EVP, Business Development C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs officer: EVP Global Marketing&Portfolio 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape officer: Executive VP Global Operations C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark officer: Exec. VP Chief Legal Officer 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell officer: Exec. VP, European Commercial 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis officer: President and CEO IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir officer: Executive VP, Global R&D 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani officer: EVP,Global Marketing&Portfolio C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX